Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | FABP1 | P07148 | 1/20 | 0.53 |
| ▸ | FABP6 | P51161 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18745740 | 0.88 | ALDH1A1 (0.51) | SMN1; SMN2LMNARAB9AMEN1KMT2A | |
| SCHEMBL10331338 | 0.86 | RAB9A (0.59) | SMN1; SMN2LMNARAB9AMEN1KMT2A | |
| SCHEMBL13757427 | 0.85 | LMNA (0.54) | SMN1; SMN2LMNARAB9AMEN1KMT2A | |
| SCHEMBL13757445 | 0.80 | NPC1 (0.74) | SMN1; SMN2LMNARAB9AMEN1KMT2A | |
| SCHEMBL19573445 | 0.79 | FABP1 (0.51) | SMN1; SMN2LMNARAB9AMEN1KMT2A | |
| SCHEMBL11563461 | 0.78 | NOS2 (0.58) | SMN1; SMN2LMNARAB9AMEN1KMT2A | |
| SCHEMBL12293177 | 0.78 | HCAR3 (0.50) | SMN1; SMN2LMNARAB9AMEN1KMT2A | |
| SCHEMBL29580298 | 0.77 | CXCR4 (0.74) | SMN1; SMN2LMNARAB9AMEN1KMT2A | |
| SCHEMBL13662122 | 0.77 | FABP1 (0.56) | SMN1; SMN2LMNARAB9AMEN1KMT2A | |
| SCHEMBL27652089 | 0.75 | FABP1 (0.54) | SMN1; SMN2LMNARAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875852-B2 | Heteroaromatic compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-29 | — | — | US | disclosed |
| US-20190112302-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-04-18 | — | — | US | disclosed |
| US-20170320867-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-09 | — | — | US | disclosed |
| US-9624229-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624229-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160031872-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-02-04 | — | — | US | disclosed |
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8735418-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140045813-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICAL, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8309566-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309566-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045813-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | SMN1; SMN2 4810/4885LMNA 3190/4885RAB9A 2803/4885 |
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | SMN1; SMN2 1767/4885LMNA 4306/4885RAB9A 1936/4885 |
| US-20170320867-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | SMN1; SMN2 4810/4885LMNA 3190/4885RAB9A 2803/4885 |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | SMN1; SMN2 2711/4885LMNA 4084/4885RAB9A 2387/4885 |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | SMN1; SMN2 2580/4885LMNA 4066/4885RAB9A 2282/4885 |
| US-20160031872-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | SMN1; SMN2 4810/4885LMNA 3190/4885RAB9A 2803/4885 |
| US-10875852-B2 | Heteroaromatic compounds as BTK inhibitors | BTK, SYK, LCK | SMN1; SMN2 4810/4885LMNA 3190/4885RAB9A 2803/4885 |
| US-20190112302-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | SMN1; SMN2 4810/4885LMNA 3190/4885RAB9A 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.